H-89
Chemical compound
From Wikipedia, the free encyclopedia
H-89 is a protein kinase inhibitor with greatest effect on protein kinase A (PKA).[2] H-89, derived from H-8 (N-[2-(methylamino)ethyl]-5-isoquinoline-sulfonamide),[3] was initially believed to act specifically as an inhibitor of PKA,[4] being 30 times more potent than H-8 at inhibiting PKA and 10 times less potent at inhibiting protein kinase G. It achieves this through competitive inhibition of the adenosine triphosphate (ATP) site on the PKA catalytic subunit.[5] However, subsequent work has suggested a variety of additional effects such as inhibition of other protein kinases (IC50 values of 80, 120, 135, 270, 2600 and 2800 nM for S6K1, MSK1, PKA, ROCKII, PKBα and MAPKAP-K1b respectively),[6] and direct inhibition of various potassium currents.[7]
| Names | |
|---|---|
| Preferred IUPAC name
N-(2-{[(2E)-3-(4-Bromophenyl)prop-2-en-1-yl]amino}ethyl)isoquinoline-5-sulfonamide | |
| Identifiers | |
3D model (JSmol) |
|
| Abbreviations | H-89 H89 |
| ChEBI | |
| ChEMBL | |
| ChemSpider | |
| DrugBank | |
| ECHA InfoCard | 100.201.023 |
| EC Number |
|
PubChem CID |
|
| UNII | |
CompTox Dashboard (EPA) |
|
| |
| |
| Properties | |
| C20H20BrN3O2S | |
| Molar mass | 446.36 g·mol−1 |
| Soluble to 25 mM | |
| Solubility in other solvents | up to 100 mM in DMSO |
| Hazards | |
| Occupational safety and health (OHS/OSH): | |
Main hazards |
Exposure may cause irritation to eyes, mucous membranes, upper respiratory tract, and skin. |
| GHS labelling:[1] | |
| Warning | |
| H302, H312, H315, H319, H332, H335 | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
| |
In addition to its use in studying mechanisms of cell signalling, H-89 has also been used experimentally in vivo. H-89 has been shown to increase the threshold and latency of pentylenetetrazol-induced seizures [8] and decrease morphine withdrawal symptoms in mice.[9]
